“Gaps like limited fast-track approval pathways, pricing regulations that may constrain R&D incentives continue to pose challenges”

As biologics, cell and gene therapies, and precision medicine reshape the global healthcare landscape, Asia-Pacific is emerging as a strategic hub for biopharmaceutical manufacturing and innovation.

- Narayan Kulkarni

In line with this transformation, Merck Life Science has expanded its Peenya facility in Bengaluru, strengthening its manufacturing footprint and supply chain capabilities across the region. The site now serves as a key hub for advanced filtration technologies, process innovation, and customer collaboration through initiatives such as M Lab. In an exclusive conversation with BioSpectrum India, Tony Qiu, Head of APAC Region, Global Plant Operations, ISCO, Merck Life Science, discusses the facility's growing role in supporting global bioprocessing needs, fostering innovation, and advancing India’s position in the global life sciences ecosystem. Edited excerpts;

What strategic factors drove the decision to expand the Peenya facility with new filtration hardware lines?

The Peenya facility has established a clear roadmap for expanding its manufacturing capabilities, built on a proven track record in engineering and producing filtration devices and consumables within controlled environments — including clean rooms that adhere to stringent cGMP guidelines. In 2026, the site marks a significant milestone with the serial production of MVP Icon swabs, signalling Peenya's entry into next-generation product manufacturing. MVP Icon is a rapid, ATP-based test designed for hygiene monitoring in the Food & Beverage industry — a product that reflects both technical sophistication and strong market relevance. This launch reinforces Peenya's position as a high-capability production node within the APAC network.